![]() Thus, RNA sequencing-based transcriptomic analysis may provide insights to pathogenesis, biomarkers and potential molecular targets for the disease. The transcriptome represents the closest genomic correlate to disease phenotype. ![]() Why is the treatment of LN challenging? Data from transcriptome analysis, novel targets and liquid biopsy A selection of representative original papers is highlighted below. 1ĭuring the period 2019–2022, the Annals of the Rheumatic Diseases published several original papers, brief reports and letters that further elucidate the pathogenesis and advance the management of LN. Of note, the all-cause and cause-specific SMR significantly decreased over time, likely reflecting the advances in the management of the disease and its comorbidities. ![]() To this end, in a recent publication from Canada, the all-cause age-specific standardised mortality ratio (SMR) was particularly high in younger (19–39 years old) patients with SLE (SMR=12.4) as compared with individuals older than 40 years (SMR=3.1). More importantly, lupus nephritis (LN) is a major cause of morbidity increasing substantially the risk for kidney failure (by up to 45×) and death (by up to 3×) especially among younger patients. Approximately 20%–40% of patients with systemic lupus erythematosus (SLE) may develop kidney disease. ![]()
0 Comments
Leave a Reply. |